Opening soon. Stay in the loop

goodmorrowJoin the opening list

Tirzepatide vs semaglutide

Tirzepatide (Zepbound) and semaglutide (Wegovy), side by side.

Updated Clinical review pending · Educational draft

The form

Two weekly injection options

The routine

A weekly routine for the injections compared here.

The evidence

A direct comparison in a human trial.

The study comparison does not decide which medicine fits an individual.

Side by side

Tirzepatide (Zepbound)Semaglutide (Wegovy)
How it worksActs on GLP-1 and GIP receptorsActs on the GLP-1 receptor
FormsWeekly injectionWeekly injection or daily pill
Average weight loss in SURMOUNT-5About 20%About 14%
Also approved forSleep apnea; type 2 diabetes as MounjaroLowering heart attack and stroke risk; type 2 diabetes as Ozempic

Side effects

Both cause the same family of side effects, mostly nausea, constipation and diarrhea while the dose rises. In SURMOUNT-5 the rates were broadly similar. A slow schedule matters more than which drug you pick.

How we choose

  • If the goal is the most weight loss, we usually start with tirzepatide.
  • If you'd rather not inject, the Wegovy pill or Foundayo.
  • The exact medication price and the ongoing self-pay total are part of the decision.
  • If you're already doing well on one, there's rarely a reason to switch.

Questions people ask

Can I switch from Wegovy to Zepbound?

Yes. We'll pick a starting dose based on where you are and how you tolerated semaglutide.

Which one has fewer side effects?

In the head-to-head trial, neither stood out. Individual people react differently, which is one reason we check in every month.

Sources

  1. Research publicationTirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) New England Journal of Medicine, 2025
  2. Research publicationTirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) New England Journal of Medicine, 2022
  3. Research publicationOnce-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) New England Journal of Medicine, 2021
  4. Manufacturer informationTirzepatide (Zepbound) prescribing information Eli Lilly, Prescribing information checked October 6, 2026
  5. Secondary sourceSemaglutide (Wegovy) prescribing information Novo Nordisk, Prescribing information checked October 6, 2026

Good days ahead.

Join the opening list for appointment updates.

Join the opening list